

DT06 Rec'd PCT/PTO 0 8 MAR 2005


Clean Version of Amended Claims

The following amendments are made with respect to the claims in the International Application PCT/EP2003/007066.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Currently amended). A compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₂ is H, C₁ to C₈ alkyl, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, C₃ to C₈ cycloalkyl, C₃ to C₈ substituted cycloalkyl, C₅ to C₆ heteroaryl, or [C₅ to C₆]-heteroaryl-(C₁ to C₆)-alkyl, and R₃ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, halogen, C₁ to C₈ alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C₁ to C₈ aminoacyl.

2 (Currently amended). The compound according to claim 1, or pharmaceutical

acceptable salts or solvates thereof, wherein:

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, or C₅ to C₆ substituted heteroaryl,

R₂ is H, CH₃, substituted alkyl or substituted phenyl, and

R₃ is substituted phenyl, C₅ to C₆ heteroaryl or C₅ to C₆ substituted heteroaryl.

3 (Currently amended). The compound according to claim 1, or pharmaceutical acceptable salts or solvates thereof, wherein:


R₁ is substituted phenyl,

R₂ is CH₃ or substituted alkyl, and

R₃ is substituted phenyl or substituted C₅ heteroaryl.

4 (Currently amended). The compound according to claim 1, having the following formula (2)

formula (2)



wherein:


R₂ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl,

R₄ is H, C₁ to C₈ alkyl, halogen, C₁ to C₈ alkoxy, carboxy, ester, amide or C₁ to C₈ aminoacyl, and

R₅ is H, C₁ to C₈ alkyl, halogen, C₁ to C₈ alkoxy, carboxy, ester, amide or C₁ to C₈ aminoacyl.

5 (Currently amended). The compound according to claim 1 having the following formula (3)

formula (3)




wherein:

R₂ is H, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, carboxy, ester, amide C₁ to C₈ aminoacyl, or C₁ to C₈ alkoxy.

6 (Currently amended). The compound according to claim 1 having the following formula (4)

formula (4)



wherein:

R₂ is H, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, carboxy, ester, amide, C₁ to C₈ aminoacyl, or C₁ to C₈ alkoxy.


7 (Currently amended). The compound according to claim 1 wherein said compound is capable of binding the NR3B1 receptor protein or a portion thereof according to SEQ ID NO. 3 or a mammalian homologue thereof.

8 (Currently amended). The compound according to claim 1 wherein said compound is capable of modulating the activity of the NR3B1 receptor protein comprising antagonistic or agonistic effects.

9 (Currently amended). A method for prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal comprising

administration of a therapeutically effective amount of a compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₂ is H, C₁ to C₈ alkyl, C₁ to C₇ acyl, [[or]] C₁ to C₇ substituted acyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, [[or]] C₇ to C₁₂ substituted phenylalkyl, C₃ to C₈ cycloalkyl, C₃ to C₈ substituted cycloalkyl,[[,]] C₅ to C₆ heteroaryl, or [C₅ to C₆]-heteroaryl-(C₁ to C₆)-alkyl, and

R₃ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, halogen, C₁ to C₈ alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C₁ to C₈ aminoacyl

wherein the prevention or treatment is directly or indirectly accomplished through the binding of said compound to the NR3B1 receptor protein or to the NR3B1 receptor protein homologue.


10 (Currently amended). The method for prevention or treatment of a NR3B1 receptor protein mediated disease or condition according to claim 9 wherein the mammal is a human.

11 (Currently amended). A method for

- i. regulating physiologies that are influenced by estrogenic response pathways in a mammal comprising modulating the activity of the NR3B1 receptor;
 - ii. treating in a mammal a disease which is directly or indirectly affected by estrogen levels;
 - iii. treating cancer, osteoporosis, obesity, lipid disorders or a cardiovascular disorder or influencing fertility and reproductive health in a mammal;
- and/or
- iv. modulating the expression of a gene directly or indirectly controlled by NR3B1 in tissues of a mammal;

wherein said method comprises administering to a mammal in need of such regulation, treatment and/or modulation an effective amount of a compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₂ is H, C₁ to C₈ alkyl, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, C₃ to C₈ cycloalkyl, C₃ to C₈ substituted cycloalkyl, C₅ to C₆ heteroaryl, or [C₅ to C₆]-heteroaryl-(C₁ to C₆)-alkyl, and

R₃ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, halogen, C₁ to C₈ alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C₁ to C₈ aminoacyl.

12 – 14 (Cancelled).

15 (Currently amended). The method of claim 11, wherein said mammal is a human.


16 (Currently amended). The method according to claim 15 for treating cancer, osteoporosis, lipid disorders or a cardiovascular disorder in humans or influencing fertility and reproductive health.

17 (Currently amended). The method according to claim 11 wherein the expression of genes comprising aromatase, MCAD, thyroid receptor alpha, osteopontin, PS2, lactoferrin is modulated.

18-26 (Cancelled).

27 (New claim). A pharmaceutical composition comprising a compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₂ is H, C₁ to C₈ alkyl, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, C₃ to C₈ cycloalkyl, C₃ to C₈ substituted cycloalkyl, C₅ to C₆ heteroaryl, or [C₅ to C₆]-heteroaryl-(C₁ to C₆)-alkyl, and

R₃ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl, C₇ to C₁₂ substituted phenylalkyl, halogen, C₁ to C₈ alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C₁ to C₈ aminoacyl;

together with a pharmaceutical carrier.